Benzoyl Peroxide

證據等級: L5

預測適應症: 4 個

Benzoyl Peroxide: From Acne Vulgaris to Vulvar Inverted Follicular Keratosis

One-Sentence Summary

Benzoyl Peroxide (BPO) is a well-established topical antimicrobial and keratolytic agent, widely recognized for its use in acne vulgaris treatment, though it holds no formal regulatory approval in Taiwan. The TxGNN model predicts it may have activity in Vulvar Inverted Follicular Keratosis, achieving a prediction score of 99.92%. However, no clinical trials and no publications currently support this direction — placing this candidate at the lowest possible evidence tier (L5, model prediction only).

Quick Overview

Item	Content
Original Indication	Not registered in Taiwan; recognized global use for acne vulgaris
Predicted New Indication	Vulvar Inverted Follicular Keratosis
TxGNN Prediction Score	99.92%
Evidence Level	L5 (Model prediction only, no actual studies)
Taiwan Market Status	✗ Not marketed (未上市)
Number of Licenses	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Benzoyl Peroxide acts primarily by releasing free radical oxygen upon contact with skin, which kills Cutibacterium acnes and exerts keratolytic activity to help clear blocked follicles. These properties underpin its well-validated efficacy in inflammatory acne vulgaris.

Inverted follicular keratosis (IFK) is a benign squamous tumor arising from the hair follicle infundibulum, presenting as a solitary papule or nodule. The pipeline’s own mechanistic rationale describes only a speculative “epidermal-follicular shared pathway” — the idea that BPO’s keratolytic action on follicular epithelium might be loosely relevant to a follicle-origin lesion. Critically, there are no structural mechanistic papers connecting BPO to IFK suppression or regression, and the “vulvar” anatomical qualifier adds a further layer of implausibility: no biological rationale supports why BPO would specifically act on vulvar IFK, a rare benign lesion that is typically managed surgically.

In short, the high TxGNN score likely reflects shared Knowledge Graph nodes in the “skin / follicular / keratosis” neighborhood, rather than any true pharmacological relationship. The prediction does not currently translate into a scientifically defensible hypothesis for clinical development.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate is backed solely by a TxGNN model prediction (L5) with zero supporting clinical or preclinical evidence, and the pipeline’s own mechanistic review explicitly characterizes the mechanistic link as “extremely weak with no structural support.” The specific vulvar anatomical target also raises unanswered tolerability questions that would need to be resolved before any further work is justified.

To proceed, the following would be needed:

Retrieval of BPO’s full mechanism of action data from DrugBank (currently a data gap)
Taiwan / US regulatory label to identify approved indications, key warnings, and contraindications
At least one peer-reviewed preclinical or mechanistic study connecting BPO activity to inverted follicular keratosis biology
A safety assessment specifically addressing topical BPO application to vulvar mucosa (irritation, sensitization, mucosal absorption risks)
Clarification of whether IFK at the vulvar site is expected to respond to topical keratolytic therapy at all, given that surgical excision is the standard of care
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.